AMARIN CORP PLC\UK

AMRN ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $20.9M
SG&A Expense $13.2M
Operating Income $-34.0M
Operating Margin
Interest Expense $2.8M
Pretax Income $-31.5M
Income Tax Expense $-901.0K
Net Income $-30.6M
Net Margin
EPS (Basic) $0.00
EPS (Diluted) $0.00
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 3 of 3 Older →